Patents Assigned to Invirsa, Inc.
  • METHODS FOR THE USE OF 5'-ADENOSINE DIPHOSPHATE RIBOSE (ADPR)
    Publication number: 20240091249
    Abstract: The present invention is directed to methods for the use of 5?-adenosine diphosphate ribose (ADPR), and compositions thereof, for treating, managing, or preventing adenovirus-related diseases or conditions, eye disorders, cancer, or diseases or conditions caused by infection, inflammation, or physical, chemical, thermal, or radiation injuries.
    Type: Application
    Filed: November 7, 2023
    Publication date: March 21, 2024
    Applicant: Invirsa, Inc.
    Inventor: Robert Shalwitz
  • Methods for the use of 5?-adenosine diphosphate ribose (ADPR)
    Patent number: 11857561
    Abstract: The present invention is directed to methods for the use of 5?-adenosine diphosphate ribose (ADPR), and compositions thereof, for treating, managing, or preventing adenovirus-related diseases or conditions, eye disorders, cancer, or diseases or conditions caused by infection, inflammation, or physical, chemical, thermal, or radiation injuries.
    Type: Grant
    Filed: August 3, 2021
    Date of Patent: January 2, 2024
    Assignee: Invirsa, Inc.
    Inventor: Robert Shalwitz
  • METHODS FOR THE USE OF 5'-ADENOSINE DIPHOSPHATE RIBOSE (ADPR)
    Publication number: 20230414647
    Abstract: The present invention is directed to methods for the use of 5?-adenosine diphosphate ribose (ADPR), and compositions thereof, for treating, managing, or preventing RNA virus-related diseases or conditions, herpes virus related diseases or conditions, Sirtuin 6 (Sirt6)-related diseases or conditions, Pax6 related diseases or conditions, and p53 related diseases or conditions.
    Type: Application
    Filed: September 11, 2023
    Publication date: December 28, 2023
    Applicant: Invirsa, Inc.
    Inventors: Robert Shalwitz, Anna Kotsakis Ruehlmann
  • Methods for the use of 5?-adenosine diphosphate ribose (ADPR)
    Patent number: 11793826
    Abstract: The present invention is directed to methods for the use of 5?-adenosine diphosphate ribose (ADPR), and compositions thereof, for treating, managing, or preventing RNA virus-related diseases or conditions, herpes virus related diseases or conditions, Sirtuin 6 (Sirt6)-related diseases or conditions, Pax6 related diseases or conditions, and p53 related diseases or conditions.
    Type: Grant
    Filed: February 9, 2021
    Date of Patent: October 24, 2023
    Assignee: Invirsa, Inc.
    Inventors: Robert Shalwitz, Anna Kotsakis Ruehlmann
  • METHODS FOR THE USE OF 5'-ADENOSINE DIPHOSPHATE RIBOSE (ADPR)
    Publication number: 20220054522
    Abstract: The present invention is directed to methods for the use of 5?-adenosine diphosphate ribose (ADPR), and compositions thereof, for treating, managing, or preventing adenovirus-related diseases or conditions, eye disorders, cancer, or diseases or conditions caused by infection, inflammation, or physical, chemical, thermal, or radiation injuries.
    Type: Application
    Filed: August 3, 2021
    Publication date: February 24, 2022
    Applicant: Invirsa, Inc.
    Inventor: Robert Shalwitz
  • Methods for the use of 5'-adenosine diphosphate ribose (ADPR)
    Patent number: 11110112
    Abstract: The present invention is directed to methods for the use of 5?-adenosine diphosphate ribose (ADPR), and compositions thereof, for treating, managing, or preventing adenovirus-related diseases or conditions, eye disorders, cancer, or diseases or conditions caused by infection, inflammation, or physical, chemical, thermal, or radiation injuries.
    Type: Grant
    Filed: February 17, 2017
    Date of Patent: September 7, 2021
    Assignee: Invirsa, Inc.
    Inventor: Robert Shalwitz
  • METHODS FOR THE USE OF 5'-ADENOSINE DIPHOSPHATE RIBOSE (ADPR)
    Publication number: 20210161936
    Abstract: The present invention is directed to methods for the use of 5?-adenosine diphosphate ribose (ADPR), and compositions thereof, for treating, managing, or preventing RNA virus-related diseases or conditions, herpes virus related diseases or conditions, Sirtuin 6 (Sirt6)-related diseases or conditions, Pax6 related diseases or conditions, and p53 related diseases or conditions.
    Type: Application
    Filed: February 9, 2021
    Publication date: June 3, 2021
    Applicant: Invirsa, Inc.
    Inventors: Robert Shalwitz, Anna Kotsakis Ruehlmann
  • Methods for the use of 5?-adenosine diphosphate ribose (ADPR)
    Patent number: 10946034
    Abstract: The present invention is directed to methods for the use of 5?-adenosine diphosphate ribose (ADPR), and compositions thereof, for treating, managing, or preventing RNA virus-related diseases or conditions, herpes virus related diseases or conditions, Sirtuin 6 (Sirt6)-related diseases or conditions, Pax6 related diseases or conditions, and p53 related diseases or conditions.
    Type: Grant
    Filed: March 26, 2019
    Date of Patent: March 16, 2021
    Assignee: Invirsa, Inc.
    Inventor: Robert Shalwitz
  • METHODS FOR THE USE OF 5'-ADENOSINE DIPHOSPHATE RIBOSE (ADPR)
    Publication number: 20200330498
    Abstract: The present invention is directed to methods for the use of 5?-adenosine diphosphate ribose (ADPR), and compositions thereof, for treating, managing, or preventing adenovirus-related diseases or conditions, eye disorders, cancer, or diseases or conditions caused by infection, inflammation, or physical, chemical, thermal, or radiation injuries.
    Type: Application
    Filed: February 17, 2017
    Publication date: October 22, 2020
    Applicant: Invirsa, Inc
    Inventor: Robert Shalwitz
  • METHODS FOR THE USE OF 5'-ADENOSINE DIPHOSPHATE RIBOSE (ADPR)
    Publication number: 20190298752
    Abstract: The present invention is directed to methods for the use of 5?-adenosine diphosphate ribose (ADPR), and compositions thereof, for treating, managing, or preventing RNA virus-related diseases or conditions, herpes virus related diseases or conditions, Sirtuin 6 (Sirt6)-related diseases or conditions, Pax6 related diseases or conditions, and p53 related diseases or conditions.
    Type: Application
    Filed: March 26, 2019
    Publication date: October 3, 2019
    Applicant: Invirsa, Inc.
    Inventors: Robert Shalwitz, Anna Kotsakis Ruehlmann